Core Insights - Certara, Inc. reported FY 2025 revenue of $418.8 million, reflecting a 9% growth, and an Adjusted EBITDA of $134.5 million, marking a 10% growth [1] - The fourth quarter revenue was $103.6 million, showing a 3% growth year-over-year, while Adjusted EBITDA decreased by 3% to $32.5 million [1][5] - For FY 2026, the company anticipates revenue growth of 0-4%, an Adjusted EBITDA margin of 30-32%, and Adjusted diluted EPS in the range of $0.44-$0.48 [1][19] Financial Performance - Fourth quarter total revenue was $103.6 million, up from $100.4 million in Q4 2024, representing a 3% increase [5][13] - Software revenue for Q4 2025 was $46.4 million, a 10% increase from $42.3 million in Q4 2024, while services revenue was $57.3 million, down 1% from $58.1 million [5][13] - Total bookings for Q4 2025 reached $155.2 million, a 7% increase year-over-year, with software bookings at $56.1 million, down 6%, and services bookings at $99.1 million, up 17% [6][7][13] Operational Insights - The company experienced a net loss of $5.9 million in Q4 2025, compared to a net income of $6.6 million in Q4 2024, primarily due to higher operating expenses [10][12] - Adjusted net income for Q4 2025 was $14.9 million, down from $24.7 million in Q4 2024, with adjusted diluted EPS at $0.09 compared to $0.15 in the previous year [12][13] - Total operating expenses for Q4 2025 were $63.6 million, an increase of $7.5 million from $56.1 million in Q4 2024, driven by higher employee-related costs and professional expenses [9][13] Strategic Outlook - The new CEO, Jon Resnick, emphasized the need for strategic focus and innovation to capture market opportunities and drive sustainable growth in 2026 [3] - The company plans to enhance its product portfolio and commercial execution throughout 2026 to improve revenue growth [3][4] - Certara's technology and customer relationships are seen as strong foundations for long-term success in the AI-enabled biosimulation and drug development market [3]

Core Insights - Certara, Inc. reported strong financial results for Q2 2025, with total revenue of $104.6 million, reflecting a year-over-year growth of 12% on a reported basis and 10% on a constant currency basis [4][8] - The company continues to see significant interest in model-informed drug development, with expectations for sustainable long-term growth driven by software enhancements and new product introductions [3][4] - Certara's adjusted EBITDA for Q2 2025 was $31.9 million, an increase of 21% compared to the same period in 2024, indicating improved operational efficiency [9][11] Financial Performance - Total revenue for Q2 2025 was $104.6 million, up from $93.3 million in Q2 2024, marking a 12% increase [4][8] - Software revenue reached $46.7 million, a 22% increase year-over-year, while services revenue was $57.9 million, growing by 5% [5][8] - Total bookings for Q2 2025 were $112.0 million, representing a 13% increase from the previous year, with software bookings at $46.6 million (11% growth) and services bookings at $65.4 million (15% growth) [6][7] Cost and Expenses - Total cost of revenues for Q2 2025 was $40.7 million, slightly up from $39.8 million in Q2 2024 [7][8] - Total operating expenses decreased to $54.3 million from $62.5 million in the same quarter last year, primarily due to a reduction in contingent consideration and transaction costs [8][10] - The net loss for Q2 2025 was $2.0 million, significantly improved from a net loss of $12.6 million in Q2 2024 [10][11] Outlook - Certara expects full-year 2025 revenue to be in the range of $415 million to $425 million, with an adjusted EBITDA margin of 30-32% and adjusted diluted earnings per share projected between $0.42 and $0.46 [15][13] - The company is confident in its full-year plan, supported by growing commercial momentum and sustained demand for its solutions [3][4]

Core Insights - Certara, Inc. reported strong financial performance in Q1 2025, with total revenue of $106.0 million, reflecting a year-over-year growth of 10% [4][8] - The company is well-positioned to capitalize on the growing adoption of biosimulation in drug development, supported by recent FDA initiatives to reduce animal testing [3][4] - Certara reiterated its full-year 2025 financial guidance, expecting revenue between $415 million and $425 million, with an adjusted EBITDA margin of 30-32% [15][20] Financial Performance - Total revenue for Q1 2025 was $106.0 million, up from $96.7 million in Q1 2024, marking a 10% increase [4][8] - Software revenue reached $46.4 million, an 18% increase year-over-year, while services revenue was $59.6 million, growing 4% [5][8] - Total bookings for Q1 2025 were $118.2 million, a 12% increase from the previous year, with software bookings growing by 23% [6][13] Profitability Metrics - Net income for Q1 2025 was $4.7 million, a significant turnaround from a net loss of $4.7 million in Q1 2024 [11][12] - Adjusted EBITDA for the quarter was $34.8 million, representing a 20% increase from $29.1 million in Q1 2024 [10][12] - Adjusted diluted earnings per share were $0.14, compared to $0.10 in the same quarter last year [12][13] Cost and Expense Management - Total operating expenses decreased to $56.9 million in Q1 2025 from $58.7 million in Q1 2024, primarily due to a reduction in contingent consideration expenses [9][11] - The cost of revenue for the quarter was $41.5 million, up from $39.3 million in the previous year, driven by increased software amortization [7][8] Market Position and Outlook - Certara's leadership in biosimulation technology positions it favorably in the biopharma industry, with over 2,400 clients globally [18] - The company continues to focus on enhancing its software and service offerings to improve drug development efficiency [3][4] - Certara's financial outlook for 2025 remains optimistic, with expectations for continued growth in both revenue and profitability metrics [15][20]